ArticleBMC infectious diseases2025
Phenotypic characteristics and carbapenemase genes in Klebsiella pneumoniae from patients at Upendra Devkota Memorial National Institute of Neurological and Allied Sciences, Kathmandu, Nepal.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- High burden of blaBMC microbiology · 2026Article
- Detection of hypervirulence genes in carbapenem resistant Klebsiella pneumoniae from cancer patients at a tertiary referral hospital in Nepal.BMC infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundCarbapenem-resistant Klebsiella pneumoniae (CRKP) has emerged as a critical nosocomial pathogen, associated with a substantial rise in morbidity and mortality. Phenotypic and molecular characterization of key carbapenemase genes in K. pneumoniae isolates is essential for understanding resistance mechanisms, guiding effective antibiotic stewardship and infection control strategies.
methodsThis cross-sectional study was conducted from November 2023 to April 2024 at Upendra Devkota Memorial National Institute of Neurological and Allied Sciences, Kathmandu. Various types of clinical specimens were collected and processed for bacterial isolation and identification. Antimicrobial susceptibility testing was performed, isolates were screened for β-lactamase production. Carbapenem-resistant isolates were subjected to mCIM and eCIM tests to detect carbapenemase. The presence of bla
resultsOut of total 812 samples, 21.2% (172/812) were culture positive. K. pneumoniae accounted for 28.5% (49/172) of isolates. More than half of the K. pneumoniae isolates were resistant to carbapenems, fluoroquinolones, aminoglycosides, nitrofurantoin and cotrimoxazole. Multidrug resistance (MDR) was observed in 73.5% (36/49) of isolates. ESBL and AmpC production were detected in 73.5% (36/49) and 44.9% (22/49) of isolates, respectively. Among 29 CRKP isolates, 62% (18/29) and 34.5% (10/29) were MBL and KPC producers respectively. Carbapenemase production was confirmed in 58.6% (17/29), while metallo-carbapenemase activity was seen in 55.1% (16/29) of CRKP isolates. The prevalence of bla
conclusionsThe study highlights the concerning prevalence of carbapenem-resistant K. pneumoniae in clinical settings, underscoring its role as a significant public health threat. Strengthening antimicrobial stewardship and implementing strict infection control measures are crucial to curb the spread of CRKP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.